"BioLamina sits at an enabling layer of the cell therapy ecosystem: rather than developing therapies directly, it produces the extracellular matrix proteins that allow researchers and companies to grow, expand, and differentiate stem cells reliably outside the body."
"Laminins are key structural components of the basement membrane, the protein layer beneath epithelial and endothelial cells, and they trigger cell-type-specific responses including adhesion, survival, differentiation, and organisation."
"BioLamina's claim is that full-length human laminins provide more biologically faithful conditions and therefore more consistent, reproducible, and clinically compliant cell products."
"The therapeutic applications for cells grown on laminin matrices are broad, potentially treating conditions such as type 1 diabetes, Parkinson's disease, heart failure, acute liver failure, and cancer."
BioLamina, a Swedish biotech company, has secured a €20 million loan from the European Investment Bank to enhance its production of laminin technologies. This funding will support the development of next-generation cell therapies and advanced, animal-free drug safety testing methods. BioLamina produces extracellular matrix proteins that facilitate the growth and differentiation of stem cells. Its core product line, Biolaminin®, consists of full-length human recombinant laminin proteins, which provide biologically faithful conditions for cell products, enhancing therapeutic applications for various diseases.
Read at TNW | Health-Tech
Unable to calculate read time
Collection
[
|
...
]